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AbstrAct
Objectives To compare definitions of high disease activity 
of the ankylosing spondylitis Disease activity score (asDas) 
and Bath ankylosing spondylitis Disease activity index 
(BasDai) in selecting patients for treatment with biologic 
disease- modifying antirheumatic drugs (bDMarDs).
Methods Patients from rheumatic Diseases Portuguese 
register ( reuma. pt) with a clinical diagnosis of axial 
spondyloarthritis (axspa) were included. Four subgroups 
(cross- tabulation between asDas (≥2.1) and BasDai (≥4) 
definitions of high disease activity) were compared regarding 
baseline characteristics and response to bDMarDs at 3 and 
6 months estimated in multivariable regression models.
Results Of the 594 patients included, the majority (82%) had 
both BasDai≥4 and asDas ≥2.1. The frequency of asDas 
≥2.1, if BasDai<4 was much larger than the opposite (ie, 
asDas <2.1, if BasDai≥4): 62% vs 0.8%. compared to 
patients fulfilling both definitions, those with asDas ≥2.1 only 
were more likely to be male (77% vs 51%), human leucocyte 
antigen B27 positive (79% vs 65%) and have a higher c 
reactive protein (2.9 (sD 3.5) vs 2.1 (2.9)). among bDMarD- 
treated patients (n=359), responses across subgroups 
were globally overlapping, except for the most ‘stringent’ 
outcomes. Patients captured only by asDas responded better 
compared to patients fulfilling both definitions (eg, asDas 
inactive disease at 3 months: 61% vs 25% and at 6 months: 
42% vs 25%).
Conclusion The asDas definition of high disease activity 
is more inclusive than the BasDai definition in selecting 
patients with axspa for bDMarD treatment. The additionally 
‘captured’ patients respond better and have higher likelihood 
of predictors thereof. These results support using asDas≥2.1 
as a criterion for treatment decisions.
InTROduCTIOn
Historically, the Bath Ankylosing Spondylitis 
Disease Activity Index (BASDAI) has been the 
most widely used measure of disease activity in 
axial spondyloarthritis (axSpA). In addition 
to other criteria (eg, the clinician’s opinion 
and failure of conventional therapy) a value 
of BASDAI ≥4 is often required, for instance 
in most clinical trials, to start treatment with 
biologic disease- modifying antirheumatic 
drugs (bDMARDs).1 2 However, this definition 
(BASDAI ≥4) is largely arbitrary. Moreover, 
BASDAI is solely based on patient- reported 
outcomes (PRO), does not weigh each vari-
able (individually or collectively) and ignores 
possible collinearity between the individual 
items.3 4
Key messages
What is already known about this subject?
 ► ankylosing spondylitis Disease activity score 
(asDas) definition of high disease activity is more in-
clusive than the Bath ankylosing spondylitis Disease 
activity index (BasDai) definition in selecting pa-
tients for treatment with biologic disease- modifying 
antirheumatic drugs (bDMarDs).
 ► Patients fulfilling both the asDas and BasDai defi-
nitions of high disease activity respond better to bD-
MarDs than those fulfilling each alone.
What does this study add?
 ► Patients exclusively fulfilling the asDas definition 
of high disease activity respond better to treatment 
and have higher likelihood of predictors thereof 
than those fulfilling both the asDas and BasDai 
definitions.
How might this impact on clinical practice?
 ► asDas ≥2.1 is the most suitable criterion to decide 
upon treatment start with bDMarDs.
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The Ankylosing Spondylitis Disease Activity Score 
(ASDAS) has been more ‘recently’ developed by the 
Assessment of SpondyloArthritis international Society 
(ASAS). Different to BASDAI, ASDAS is a composite 
disease activity instrument which incorporates both 
objective inflammatory markers such as C reactive 
protein (CRP) and PROs (back pain, duration of 
morning stiffness, patient global assessment and periph-
eral joint pain).5 6 CRP has been previously and consis-
tently shown to predict response to bDMARDs.7–12 
Importantly, unlike BASDAI, for which no cut- offs have 
been validated, four disease activity states were defined 
and validated for ASDAS: inactive disease (ASDAS<1.3), 
low (1.3≤ASDAS<2.1), high (2.1≤ASDAS≤3.5) and very 
high disease activity (ASDAS>3.5).13 14 Over the years, 
ASDAS has been ‘challenged’ in several independent 
cohorts and it has consistently shown to perform well in 
capturing treatment effects.15–18
Despite the above- mentioned advantages of ASDAS 
over BASDAI in measuring disease activity in patients 
with axSpA, evidence supporting that ASDAS can possibly 
replace BASDAI for selecting patients for treatment 
with bDMARD is still scarce. A previous cross- sectional 
study in patients with radiographic axSpA (r- axSpA) has 
shown that ASDAS high disease activity (≥2.1) captures 
more patients otherwise missed by BASDAI (≥4) (37% 
patients had ASDAS≥2.1 and BASDAI<4).12 In addition, 
data from a small prospective cohort study (n=289) has 
shown that patients who fulfil the ‘ASDAS criterion’ 
alone (ie, ASDAS≥2.1 and BASDAI<4) respond well 
to tumor necrosis factor inhibitors (TNFi), although 
better results were seen in patients fulfilling both criteria 
(ASDAS≥2.1 and BASDAI≥4).19 These preliminary data 
suggest that using only BASDAI≥4 as the eligibility crite-
rion for treatment start, as mostly done so far, excludes 
patients with potential to benefit from therapy with TNFi 
or eventually with other bDMARDs. Therefore, for the 
first time, ASAS experts prescribed the use of ASDAS 
(≥2.1), in addition to BASDAI (≥4), to select patients to 
start bDMARD treatment, in the recent update on ASAS- 
European League Against Rheumatism (EULAR) recom-
mendations for the management of axSpA.20 However, 
evidence favouring ASDAS is still limited and further 
data are warranted to eventually strengthen or modify 
this endorsement. We aimed to compare the definitions 
of high disease activity according to ASDAS and BASDAI 
in selecting patients for treatment with bDMARDs.
MeTHOds
Patients and study design
In this prospective multicentre cohort study patients 
(≥18 years old) with axSpA, according to their treating 
rheumatologists (both treated and not treated with a first 
bDMARD), registered in Rheumatic Diseases Portuguese 
Register ( Reuma. pt) from June 2008 to May 2018, were 
included. In addition, patients were required to have 
complete 6 months of follow- up (ie, baseline, 3- month 
and 6- month visits), as well as complete data on ASDAS 
and BASDAI at baseline (‘eligible population’).  Reuma. 
pt is a nationwide clinical register, established and 
managed by the Portuguese Society of Rheumatology, in 
which data from patients with various rheumatic diseases, 
including axSpA, are recorded. A detailed report of the 
design of  Reuma. pt and data management procedures 
has been published elsewhere.21 For the current study, 
a dedicated team of researchers from each participating 
centre was assigned to compare information on a core 
set of socio- demographic and clinical variables between 
the central database and the medical records, in order 
to complete missing information whenever possible. 
Patients have signed a written informed consent before 
inclusion.
disease activity measurements
The BASDAI is composed of six questions (either scored 
on a numerical rating scale or on a 10 cm visual analogue 
scale) that assess fatigue (1), spinal pain (2), periph-
eral joints (3), entheses (4), intensity of morning stiff-
ness (5) and duration of morning stiffness (6). The total 
BASDAI score is calculated by summing the first four 
questions and the average of the last two questions and 
by dividing the result by 5. The score ranges from 0 (no 
disease activity) to 10 (very active disease). A cut- off of 4 
is frequently used to define active disease, but this cut- off 
level does not have a firm justification.1 2 22
The ASDAS is a data- driven index that combines three 
BASDAI- PRO- derived questions about spinal pain (1), 
peripheral joints (2) and duration of morning stiffness 
(3), as well as the ‘patient global assessment of disease 
activity’ (4), with either the CRP (ASDAS- CRP) or the 
erythrocyte sedimentation rate (ESR) (ASDAS- ESR) (5) 
according to a weighted formula. The ASDAS- CRP is 
recommended by ASAS, both for use in clinical practice 
and in clinical trials. The ASDAS has formally validated 
cut- off levels for disease activity states: an ASDAS value 
below 1.3 is considered inactive disease, 1.3 or higher 
and lower than 2.1 low disease activity, between 2.1 and 
3.5 high disease activity, and above 3.5 very high disease 
activity.13 14 22
demographic and clinical characteristics
The following information were collected: (1) socio- 
demographic: age, gender, body mass index (mg/
m2), smoking status (smoker/non- smoker); (2) clin-
ical and laboratory: disease duration (years), CRP as 
continuous (mg/dL), Bath Ankylosing Spondylitis 
Functional Index (BASFI) and the number of comor-
bidities (which included arterial hypertension, dyslip-
idaemia, diabetes, cardiovascular diseases, thyroid 
disease and malignancies); (3) SpA features (used to 
assess the ASAS axSpA classification criteria) all as ever 
(ie, current or past) and binary (yes/no): inflammatory 
back pain (no formal definition), peripheral arthritis, 
uveitis, inflammatory bowel disease (Crohn’s/colitis), 
psoriasis, dactylitis, heel enthesitis, good response 
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Figure 1 Flow chart representing sample selection 
based on inclusion/exclusion criteria and type of analysis. 
* ASAS20, ASAS40, ASAS PR, ASDAS CII, ASDAS MI, 
ASDAS ID and BASDAI 50 response. ASAS, Assessment of 
SpondyloArthritis international Society; ASDAS, Ankylosing 
Spondylitis Disease Activity Score; ASDAS CII, ASDAS 
clinically important improvement; ASDAS ID, ASDAS inactive 
disease; ASDAS MI, ASDAS major improvement; axSpA, 
axial spondyloarthritis; BASDAI, Bath Ankylosing Spondylitis 
Disease Activity Index; bDMARD, biologic disease- modifying 
antirheumatic drugs.
to non- steroidal anti- inflammatory drugs (NSAIDs), 
elevated CRP (≥0.5 mg/dL), human leucocyte antigen 
B27 status (HLA- B27) and familial history of SpA23; (4) 
imaging: presence of sacroiliitis on pelvic radiographs, 
according to the modified New York criteria (mNY), and 
on MRI (both according to the treating rheumatologists/
local radiologists)24 and (5) treatment: bDMARDs used 
(namely infliximab, etanercept, adalimumab, certoli-
zumab pegol, golimumab or secukinumab) and past and 
current co- medication (NSAIDs, oral glucocorticoids and 
conventional synthetic DMARDs (csDMARDs)).
Treatment outcomes
Treatment effect was assessed according to ASAS20 (main 
outcome) and ASAS40 responses, ASAS partial remission 
(ASAS PR), ASDAS clinically important improvement 
(ASDAS CII) and ASDAS major improvement (ASDAS 
MI), ASDAS inactive disease (ASDAS ID) and BASDAI 50 
response (ie, improvement of BASDASI of ≥50% and/or 
absolute improvement of 2 units).21
statistical analysis
Patients were grouped into four categories according 
to the cross- tabulation of baseline ASDAS and BASDAI: 
(1) ASDAS≥2.1 and BASDAI≥4; (2) ASDAS≥2.1 and 
BASDAI<4; (3) ASDAS<2.1 and BASDAI≥4 and (4) 
ASDAS<2.1 and BASDAI<4. The probability of fulfilling 
the ASDAS definition of high disease activity irrespec-
tive of the BASDAI definition and vice versa (marginal 
probabilities) and the probability of fulfilling each defi-
nition conditional on the other were calculated. The four 
disease activity subgroups were compared with respect to 
baseline demographic and clinical characteristics across 
all patients included (‘eligible population’). χ2 test was 
used to test between- group differences for categorical 
variables and the independent sample t- test or one- way 
analysis of variance for continuous variables, as appro-
priate.
Response to treatment at 3 and 6 months was 
compared across the four disease activity subgroups, in 
patients starting treatment with their first bDMARD and 
with complete follow- up data on all above- mentioned 
response outcomes (‘efficacy population’). Given the 
observational setting of our study, treatment response 
was estimated in multivariable logistic regression models, 
adjusting for factors, selected a priori, that have been 
shown to influence the response to TNFi and as such 
might confound the comparisons across subgroups, that 
is, age, gender, CRP and BASFI at baseline, and expressed 
as an estimated probability of response (with 95% CI). 
Patients were considered treatment responders if they 
met the clinical response criteria at the particular time 
point of analysis.
All analyses were repeated in patients who, in addition 
to the clinical diagnosis, also fulfilled the ASAS axSpA 
classification criteria. Data analysis was performed using 
Stata V. 14.
ResulTs
Patient characteristics
In total, 3138 patients with axSpA were registered in 
Reuma. pt by the time of database lock (May 2018). From 
these, 594 fulfilled the inclusion criteria (‘eligible popu-
lation’) (figure 1). Patients eligible for the study were 
largely similar to the entire  Reuma. pt axSpA population 
except for higher baseline levels of disease activity and 
higher number of patients under bDMARD in the former 
(online supplementary table 1). Out of the 594 included 
patients 529 were starting their first bDMARD, and out of 
these 359 had complete data for all response outcomes at 
every time point (‘efficacy population’) (online supple-
mentary table 2).
Baseline characteristics are shown in table 1 for the 
‘eligible population’ and the ‘efficacy population’. 
Overall, 55% were men and 67% HLA- B27 positive, with 
Protected by copyright.
 o
n
 M
arch 13, 2020 at UNL/Fac Ciencias M
edicas Biblioteca.
http://rm
dopen.bmj.com/
R
M
D
 O
pen: first published as 10.1136/rm
dopen-2019-001145 on 5 M
arch 2020. Downloaded from
 
4 Marona J, et al. RMD Open 2020;6:e001145. doi:10.1136/rmdopen-2019-001145
RMD Open
Table 1 Baseline patient and disease characteristics
Variables
All axSpA 
(‘eligible 
population’)
(n=594)
bDMARD 
treated with full 
data (‘efficacy 
population’) 
(n=359)
Age in years, mean±SD 49±13 49±12
Gender (male), n (%) 326 (55) 195 (54)
BMI in kg/m2, mean±SD (n=300) 25.9±4.7 25.6±4.4
Current smokers, n (%)* 114 (22) 75 (23)
Number of comorbidities, mean±SD† 
(n=434)
0.3±0.6 0.3±0.6
Disease duration in years, mean±SD* 12.8±10.3 12.7±9.9
Inflammatory back pain, n (%)* 436 (84) 271 (85)
Peripheral arthritis, n (%)* 211 (40) 139 (43)
HLA- B27, n (%)* 347 (67) 207 (65)
Radiographic sacroiliitis (mNY), n (%) 
(n=487)
391 (80) 250 (82)
Sacroiliitis on MRI- SIJ, n (%) (n=225) 137 (61) 77 (56)
Number of SpA features±SD* 2.5±1.2 2.5±1.3
BASDAI (0–10), mean±SD 5.8±2.1 6.0±1.8
BASDAI≥4, n (%) 491 (83) 319 (89)
ASDAS- CRP, mean±SD 3.5±1.0 3.7±0.9
  ASDAS inactive disease, n (%) 9 (2) 0 (0)
  ASDAS low disease activity, n (%) 28 (5) 7 (2)
  ASDAS high disease activity, n (%) 272 (46) 162 (45)
  ASDAS very high disease activity, 
n (%)
285 (48) 190 (53)
CRP, mg/dL, mean±SD* 2.1±2.9 2.1±2.8
  Elevated CRP, n (%)‡* 376 (71) 260 (72)
BASFI (0–10), mean±SD* 5.2±2.5 5.4±2.4
bDMARD, n (%)     
  Infliximab 130 (25) 87 (24)
  Adalimumab 164 (31) 115 (32)
  Etanercept 135 (26) 91 (25)
  Golimumab 91 (17) 60 (17)
  Certolizumab pegol 5 (1) 3 (1)
  Secukinumab 4 (1) 3 (1)
Previous co- medication, n (%):     
  NSAIDs 211 (40) 145 (40)
  csDMARDs 271 (51) 195 (54)
  Oral steroids 108 (20) 80 (22)
‘Eligible population’: axSpA patients, irrespective of being treated with bDMARD, 
with complete 6 months of follow- up and BASDAI/ASDAS data at baseline 
(irrespective of having ASDAS/BASDAI at any other time point). ‘Efficacy 
population’: axSpA patients treated with bDMARD, with complete 6 months of 
follow- up and complete data on all response outcomes (every time point).
*Variables with <15% of missing data.
†Arterial hypertension and other cardiovascular diseases, dyslipidaemia, diabetes 
mellitus, thyroid disease and malignancies.
‡Defined as ≥0.5 mg/dL.
ASDAS, Ankylosing Spondylitis Disease Activity Score; axSpA, axial 
spondyloarthritis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; 
BASFI, Bath Ankylosing Spondylitis Functional Index; bDMARD, biologic disease- 
modifying antirheumatic drugs; BMI, body mass index; CRP, C reactive protein; 
csDMARDs, conventional synthetic disease- modifying antirheumatic drugs; 
HLA- B27, human leucocyte antigen B27; mNY, modified New York criteria for 
ankylosing spondylitis; MRI- SIJ, MRI of sacroiliac joints; NSAIDs, non- steroid anti- 
inflammatory drugs.
Table 2 Subgroups according to BASDAI/ASDAS category 
(baseline)
ASDAS≥2.1 ASDAS<2.1 Total
BASDAI≥4 487 4 491
BASDAI <4 64 39 103
Total 551 43 594*
*Subgroups according to BASDAI/ASDAS category at baseline 
in the ‘eligible population’ (ie, treated or not with bDMARD, with 
complete 6 months of follow- up).
ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, 
Bath Ankylosing Spondylitis Disease Activity Index; bDMARD, 
biologic disease- modifying antirheumatic drug.
a mean disease duration of 13 years. Patients from the 
‘efficacy population’ were largely similar to the ‘eligible 
population’.
Comparison across disease activity subgroups: baseline 
characteristics
The cross- tabulation between the ASDAS definition of high 
disease activity (cut- off ≥2.1) and the BASDAI definition 
of high disease activity (cut- off ≥4), in the ‘eligible popu-
lation’, is shown in table 2. The probability of fulfilling 
the ASDAS definition was higher (93%) compared to the 
probability of fulfilling the BASDAI definition (83%). Most 
patients fulfilled both definitions (n=487; 82%) and only 
a minority fulfilled neither (n=39; 7%). The conditional 
probability of having an ASDAS≥2.1, when BASDAI <4 was 
much higher than the probability of ASDAS<2.1 among 
those with BASDAI ≥4 (62% vs 0.8%).
Compared to patients who fulfilled both (ASDAS and 
BASDAI) definitions, those who fulfilled only the ASDAS 
definition were more likely to be male (77% vs 51%) and 
HLA- B27 positive (79% vs 65%) (table 3). In addition, the 
levels of CRP were higher (2.9 (SD 3.5) vs 2.1 (2.9) mg/
dL) and BASFI was lower (3.0 (2.0) vs 5.6 (2.2)) among 
patients fulfilling the ASDAS definition only compared to 
those fulfilling both.
Comparison across disease activity subgroups: response to 
bdMARds
Table 4 shows the adjusted response to bDMARDs at 3 
and 6 months for the four disease activity subgroups. 
Overall good response to bDMARDs was observed (eg, 
ASDAS CII 61% and 66% at 3 and 6 months, respec-
tively). Outcomes were largely overlapping between 
patients with high disease activity according to the ASDAS 
definition, irrespective of BASDAI. But for the most ‘diffi-
cult’ to achieve outcomes (ie, ASAS PR and ASDAS ID), 
the likelihood of response was significantly higher in the 
subgroup fulfilling the ASDAS definition alone compared 
to the subgroup fulfilling both the ASDAS and BASDAI 
definitions: ASAS PR at 3 months 61% vs 22% and ASDAS 
ID at 3 months 61% vs 25%. Patients with ASDAS <2.1 at 
baseline (regardless of BASDAI) were too few (n=10) to 
allow a meaningful assessment of treatment effects.
sensitivity analysis: patients fulfilling the AsAs classification 
criteria for axspA
From the 594 included patients (‘eligible population’), 463 
(78%) fulfilled the ASAS classification criteria for axSpA. 
Out of these, 286 were starting their first bDMARD and had 
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Table 3 Baseline patient and disease characteristics in the entire ‘eligible population’ and across all subgroups according to 
BASDAI/ASDAS category
Variables
Overall
(n=594)
ASDAS≥2.1 ASDAS<2.1
P value*
BASDAI≥4
(n=487)
BASDAI <4
(n=64)
BASDAI≥4
(n=4)
BASDAI <4
(n=39)
Age in years, mean±SD 49±13 49±12 48±14 42±9 48±15 0.66
Gender (male), n (%) 326 (55) 251 (51) 49 (77) 1 (25) 25 (64) <0.01
BMI in kg/m2, mean±SD (n=300) 25.9±4.7 26.0±4.8 24.7±4.5 . (.) 26.0±3.6 0.28
Current smokers, n (%) 114 (22) 98 (23) 10 (19) 0 (0) 6 (19) <0.01
Age at diagnosis in years, mean±SD (n=449) 36±12 36±12 34±11 29±15 40±13 0.08
Disease duration in years, mean±SD† 12.8±10.3 12.9±10.1 14.1±12.4 13.1±6.9 8.3±8.2 0.08
HLA- B27, n (%)† 347 (67) 278 (65) 44 (79) 2 (67) 23 (68) 0.24
Radiographic sacroiliitis (mNY), n (%) (n=487) 391 (80) 322 (80) 44 (85) 3 (100) 22 (76) 0.63
Sacroiliitis on MRI- SIJ, n (%) (n=225) 137 (61) 114 (60) 9 (50) 2 (100) 12 (86) 0.12
Number of SpA features±SD† 2.5±1.2 6.4±1.5 2.9±1.0 5.3±0.8 1.9±1.3 0.96
BASDAI (0–10), mean±SD 5.8±2.1 6.4±1.5 2.9±0.9 5.3±0.8 1.9±1.3 <0.01
ASDAS- CRP, mean±SD 3.5±1.0 3.8±0.8 3.0±0.6 1.9±0.3 1.6±0.4 <0.01
  ASDAS inactive disease, n (%) 9 (2) 0 (0) 0 (0) 0 (0) 9 (23) <0.01
  ASDAS low disease activity, n (%) 28 (5) 0 (0) 0 (0) 3 (75) 25 (64)
  ASDAS high disease activity, n (%) 272 (46) 213 (44) 53 (83) 1 (25) 5 (13)
  ASDAS very high disease activity, n (%) 285 (48) 274 (56) 11 (17) 0 (0) 0 (0)
CRP, mg/dL, mean±SD† 2.1±2.9 2.1±2.9 2.9±3.5 0.1±0.0 0.5±0.7 0.03
  Elevated CRP, n (%)‡ 376 (71) 325 (70.4) 47 (88.7) 0 (0.0) 4 (33.3) <0.01
BASFI (0–10), mean±SD† 5.2±2.5 5.6±2.2 3.0±2.0 4.7±0.6 2.1±2.0 <0.01
bDMARD therapy (n=529) (n=462) (n=53) (n=2) (n=12) §
  Infliximab, n (%) 130 (25) 112 (24) 12 (23) 0 (0) 130 (25)   
  Adalimumab, n (%) 164 (31) 142 (31) 18 (34) 0 (0) 164 (31) 0.18
  Etanercept, n (%) 135 (26) 116 (25) 18 (34) 2 (26) 135 (26)   
  Golimumab, n (%) 91 (17) 83 (18) 5 (9) 0 (0) 91 (17)   
  Certolizumab pegol, n (%) 5 (1) 5 (1) 0 (0) 0 (0) 5 (1)   
  Secukinumab, n (%) 4 (1) 4 (1) 0 (0) 0 (0) 4 (1)   
Co- medication (bDMARD- treated), n (%)             
  NSAIDs 211 (40) 184 (40) 21 (40) 1 (50) 5 (42) 0.99
  csDMARDs 271 (51) 234 (51) 28 (53) 2 (100) 7 (58) 0.52
  Oral corticosteroids 108 (20) 95 (21) 11 (21) 1 (50) 1 (8) 0.54
Overall (‘Eligible population’): axSpA patients, irrespective of being treated with bDMARDs, with complete 6 months of follow- up and BASDAI/
ASDAS data at baseline (irrespective of having ASDAS/BASDAI at any other time point).
*Comparison across all subgroups according to BASDAI/ASDAS category of disease activity (ANOVA test for continuous variables and χ2 test 
for categorical variables). P values in bold are significant (<0.05).
†Variables with <15% of missing data.
‡Defined as ≥0.5 mg/dL.
§P value of <0.01 for the categorical variable (treated or not with bDMARD).
ASDAS, Ankylosing Spondylitis Disease Activity Score; axSpA, axial spondyloarthritis; BASDAI, Bath Ankylosing Spondylitis Disease Activity 
Index; BASFI, Bath Ankylosing Spondylitis Functional Index; bDMARD, biologic disease- modifying antirheumatic drug; BMI, body mass index; 
CRP, C reactive protein; csDMARDs, conventional synthetic disease- modifying antirheumatic drugs; HLA- B27, human leucocyte antigen B27; 
mNY, modified New York criteria for ankylosing spondylitis; MRI- SIJ, MRI of sacroiliac joints; NSAIDs, non- steroid anti- inflammatory drugs.
complete data for all response outcomes. These popula-
tions showed similar baseline characteristics between each 
other and the ‘eligible population’ (online supplementary 
table 3). Results of the sensitivity analyses are similar to the 
ones from the main analysis (online supplementary tables 
4- S6).
dIsCussIOn
In this prospective cohort study, we have shown that applying 
the ASDAS definition of high disease activity (≥2.1) leads to 
more patients with axSpA being selected to start treatment 
with bDMARDs, compared to the ‘traditional’ BASDAI 
definition (≥4). Importantly, the additionally ‘captured’ 
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Table 4 Response to bDMARD in the ‘efficacy population‘ according to the BASDAI/ASDAS category
Variables
Overall ASDAS ≥ 2.1 ASDAS < 2.1
(n=359)
BASDAI ≥ 4
(n=318)
BASDAI < 4
(n=31)
BASDAI ≥ 4
(n=1)
BASDAI < 4
(n=9)
Probability of response (95% CI)
Outcomes: 3 months
  ASAS20 60 (55; 64) 60 (55; 65) 58 (45; 70) * *
  ASAS40 41 (36; 46) 43 (38; 49) 26 (13; 39) * 40 (7; 73)
  ASAS PR 26 (22; 30) 22 (18; 26) 61 (50; 72) * 44 (17; 72)
  BASDAI50 61 (56; 66) 62 (57; 67) 58 (46; 70) * 44 (17; 72)
  ASDAS CII 61 (56; 66) 62 (57; 67) 68 (56; 80) * *
  ASDAS MI 37 (32; 41) 38 (33; 43) 32 (22; 42) * *
  ASDAS ID 29 (25; 33) 25 (21; 30) 61 (49; 74) * 56 (25; 86)
Outcomes: 6 months
  ASAS20 63 (58; 68) 63 (57; 68) 65 (49; 80) * *
  ASAS40 40 (35; 44) 42 (37; 47) 23 (12; 34) * 40 (7; 73)
  ASAS PR 28 (24; 32) 25 (21; 30) 52 (39; 65) * *
  BASDAI50 64 (59; 69) 66 (61; 71) 48 (35; 61) * 44 (17; 72)
  ASDAS CII 66 (62; 71) 69 (64; 73) 61 (50; 72) * *
  ASDAS MI 39 (34; 43) 41 (36; 46) 35 (26; 44) * *
  ASDAS ID 28 (24; 32) 25 (21; 30) 42 (30; 54) * *
Overall (‘Efficacy population’): axSpA patients treated with bDMARD, with complete 6 months of follow- up and complete data on all 
response outcomes (every time point). Estimated probability of response across all subgroups according to BASDAI/ASDAS category of 
disease activity using a logistic regression model adjusted for age, gender, CRP and BASFI.
*Models fail to converge.
ASAS PR, ASAS partial remission; ASDAS, Ankylosing Spondylitis Disease Activity Score; ASDAS CII, ASDAS clinically important 
improvement; ASDAS ID, ASDAS inactive disease ; ASDAS MI, ASDAS major improvement; BASDAI, Bath Ankylosing Spondylitis 
Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; bDMARD, biologic disease- modifying antirheumatic drug; 
CRP, C reactive protein.
patients have a higher likelihood of having known predic-
tors of response to bDMARDs, for example, male gender, 
lower BASFI, higher CRP and indeed respond better, as 
confirmed by stringent outcomes such as ASAS PR and 
ASDAS ID. These results support the use of ASDAS≥2.1 as 
a criterion for treatment decisions in axSpA.
Our results are in line with previous studies also reporting 
ASDAS high disease activity as more inclusive than BASDAI 
in the selection of patients with axSpA for bDMARD treat-
ment.12 19 This finding is also in accordance with the overall 
‘clinical impression’ that the use of ASDAS expands the 
spectrum of patients that can benefit from treatment with 
bDMARDs. Obviously, the consequent relevant question is 
whether these ‘additional’ patients qualifying for bDMARD 
treatment really benefit from it, at least as much as those 
already captured by the BASDAI. Our results do support 
this claim in two complementary ways: (1) first, the patients 
fulfilling the ASDAS definition only (ie, ASDAS ≥2.1 and 
BASDAI <4) show a higher likelihood (compared to those 
fulfilling both) of baseline (pre- treatment) characteristics 
that have been consistently shown to be associated with 
a higher likelihood of response to bDMARDs (ie, male 
gender, HLA- B27 positivity, elevated CRP and lower level 
of disability as measured by BASFI)7–12 and (2) second, the 
patients who fulfil the ASDAS definition only show a similar 
response to bDMARDs or even better (for the most ‘strin-
gent’ outcomes; ie, ASDAS ID and ASAS PR), compared to 
patients fulfilling both definitions.
These results must be interpreted considering the 
study setting.  Reuma. pt includes axSpA patients, seen 
by rheumatologists in daily clinical practice in Portugal 
since 2008. Already in 2011, the Portuguese recommen-
dations for the use of biological therapies in axSpA for 
the first time prescribed the use of either ASDAS≥2.1 or 
BASDAI ≥4 to select patients for bDMARD treatment.25 
Although no formal criteria were required in our study, 
almost all patients fulfilled either the ASDAS and/or the 
BASDAI definitions at baseline (93% for the ‘eligible 
population’, data in table 2). In addition, the proportion 
of patients captured by the ASDAS definition only among 
patients otherwise not captured (ie, with a BASDAI <4) 
was impressive: 62% for the ‘eligible population’. This 
percentage is similar as compared to a previous study in 
Norway (66%), and even higher if, as done in the latter, 
we only consider the patients in whom a bDMARD was 
started, that is, the ‘efficacy population’, with the ASDAS 
definition only capturing 78% of the patients (data not 
shown).18 Of note, the use of ASDAS as a criterion to 
start biological therapy was only considered in the 2016 
update of the ASAS- EULAR recommendations for the 
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management of axSpA and is not mandatory in Norway. 
This suggests that Portuguese rheumatologists not only 
have been ‘pioneering’ the application of ASDAS for 
treatment decisions, but also strongly comply with the 
national recommendations.
As in previous studies, patients starting bDMARD treat-
ment and fulfilling both definitions (ASDAS and BASDAI) 
had higher pre- treatment disease activity (ASDAS: 3.8 
(0.8)) compared to patients fulfilling the ASDAS defini-
tion only (ASDAS: 3.0 (0.6)).19 Since high disease activity 
predicts good response to bDMARDs, higher response 
rates would be expected in the subgroup fulfilling both 
the ASDAS and BASDAI definitions. However, this was 
not what we have found. In fact, for most of the outcomes, 
the response was largely overlapping between the two 
subgroups, and for the most ‘stringent’ (ie, ASAS PR and 
ASDAS ID) response was even higher in the subgroup 
fulfilling the ASDAS definition only. Despite the fact that 
the higher likelihood of ASDAS ID and ASAS PR can 
be, mathematically, explained by lower baseline values 
of each score individual components (thus, easier to 
achieve), one alternative and compelling explanation 
may reside in the higher likelihood of other features also 
associated with better response, such as male gender, 
HLA- B27 positivity and lower BASFI that were more 
common in patients fulfilling the ASDAS definition only.
Our study has some noteworthy limitations. First, the 
number of ‘eligible’ patients from the overall  Reuma. pt 
cohort is rather small as a result of missing data in the 
variables of interest (ie, ASDAS and BASDAI), which 
may limit the external validity of the findings. However, 
this is a common problem in ‘clinical- practice’ cohorts 
(registries). Moreover, the ‘eligible population’ is largely 
comparable to the complete  Reuma. pt cohort, except 
for disease activity which is larger in the former (’eligible 
population’). This is not unexpected, since the ‘eligible 
population’ had a larger proportion of patients starting 
bDMARD therapy. Nevertheless, the response rate in 
our study is somewhat higher than what is usually seen 
in clinical trials and also in previous cohorts suggesting 
possible ‘selection bias’. Notwithstanding, this is unlikely 
to affect our comparison between subgroups defined by 
ASDAS and BASDAI disease activity definitions, since 
this ‘possible bias’ would affect all equally. Second, given 
the low number of patients we were not able to mean-
ingfully assess the bDMARD efficacy in patients fulfilling 
neither the ASDAS nor the BASDAI criteria. However, 
this is merely a reflection of clinical practice and previous 
studies have already shown that these patients (even if 
selected by rheumatologists to start biological therapy) 
respond worse compared with patients fulfilling at least 
one selection criterion. Third, since almost all patients 
fulfilling the ASAS criteria were also mNY- positive (86%) 
we could not investigate whether there were differences 
between patients with r- axSpA and non- radiographic 
axSpA (nr- axSpA). Again, this reflects the current clinical 
practice in our country (where only recently TNFi have 
been approved for nr- axSpA), but given the extensive 
literature showing no meaningful differences in disease 
burden between nr- axSpA and r- axSpA it is unlikely that 
our results would be different in these patients.25–29
In conclusion, both BASDAI and ASDAS perform 
well in selecting patients with axSpA for treatment with 
bDMARDs in daily clinical practice. Ignoring ASDAS 
as a selection criterion yields an unacceptable number 
of patients being excluded from an intervention from 
which they would most likely benefit. Additionally, 
patients exclusively captured by the ASDAS definition 
of high disease activity (≥2.1) respond better to treat-
ment and have a higher likelihood of predictors thereof. 
Therefore, the ASDAS should be at least used in addition 
to BASDAI, and most likely exclusively, when selecting 
patients for treatment with bDMARDs.
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